Global Ulcerative Colitis Market 2024 - By Growth Opportunities, Future Insights, Regional Segments, Latest Innovations And Forecast To 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Ulcerative Colitis Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The ulcerative colitis market size has grown strongly in recent years. It will grow from $6.84 billion in 2023 to $7.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to prevalence of ulcerative colitis, innovations in drug development, biologics and targeted therapies, improved treatment guidelines, patient advocacy and support groups.

The ulcerative colitis market size is expected to see strong growth in the next few years. It will grow to $9.48 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in telemedicine, focus on early intervention, biosimilars market growth, research in gut microbiome, emergence of novel therapies. Major trends in the forecast period include patient-centric approaches, global collaborations in research, integration of digital health solutions, innovations in drug delivery, topical and localized therapies.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=10328&type=smp

Market Segmentation:
The ulcerative colitis market covered in this report is segmented -
1) By Drug Type: Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, Other Drug Types
2) By Disease Type: Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis
3) By Molecule Type: Biologics, Small Molecules
4) By Route of Administration: Oral, Injectables
5) By End-User: Hospital Pharmacies, Retail Pharmacies, Drug Store, Other End-User

Major Driver - Fueling Growth Ulcerative Colitis Market Expands With The Surge In Healthcare Expenditure
The increasing healthcare expenditure is expected to propel the growth of the ulcerative colitis market going forward. Health expenditure refers to all spending for health-related services, family planning activities, nutrition activities, and emergency help, but excludes expenses for drinking water and sanitation. Increased healthcare spending can benefit ulcerative colitis sufferers by improving access to medical care and therapies. Hospitalization for ulcerative colitis can be significant, and hospital readmissions for flares can result in higher mortality and healthcare costs. For instance, in March 2022, according to the 2021-2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, the annual increase in national health spending was predicted to average 5.1% between 2021 and 2030, reaching approximately $6.8 trillion by 2030. Additionally, throughout the period 2021-2030, Medicare expenditures are expected to expand at a 7.2% annual rate, while Medicaid spending is expected to grow at a 5.6% annual rate. Therefore, increasing healthcare expenditures are driving the growth of the ulcerative colitis market.

Competitive Landscape:
Major companies operating in the ulcerative colitis market report are Abbott Laboratories, AbbVie Inc., Ajinomoto Co. Inc., AstraZeneca plc, Bausch Health Companies Inc., Eli Lilly and Co., Johnson & Johnson, Index Pharmaceuticals Holdings AB, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Allergan plc, Bayer AG, BioLineRx Ltd., Celgene Corporation, Bristol Myers Squib Company, Takeda Pharmaceutical Company Limited, Genentech Inc., UCB S.A., Protagonist Therapeutics, Shire plc, Warner Chilcott, Prometheus Laboratories Inc., Cosmo Pharmaceuticals, Dr. Falk Pharma GmbH, Tillotts Pharma AG, Ferring Pharmaceuticals Inc., Salix Pharmaceuticals Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

Top Trend - Revolutionizing IBD Diagnosis Clario Ert Inc., Gi Reviewers Llc, And Rsip Vision Unveil AI Technology For Enhanced Ulcerative Colitis Scoring
Technological advancements are a key trend gaining popularity in the ulcerative colitis market. Companies operating in the ulcerative colitis market are adopting new technologies to sustain their position in the market. For instance, in March 2023, Clario ERT Inc., a US-based healthcare research and technology firm, and GI Reviewers LLC, a US-based pharmaceutical reviews and assessment organization, along with RSIP Vision, an ISRAEL-based software company, released their innovative and human-level AI technology-based rating system to improve efficiency and consistency of inflammatory bowel disease (IBD) scoring, such as ulcerative colitis (UC) and Crohn's disease scoring. The method is projected to enhance the repeatability of colonoscopy video scoring, streamline workflow by reducing the time necessary for a human expert reader to score, and, eventually, boost recruitment and lower clinical trial expenses. The performance of algorithms, as measured by the Kappa metric technology, was shown to be equivalent to that of human reviewers. The algorithm was trained on hundreds of films from various sites and devices, comprising over 100,000 photos, all of which were assessed by an expert gastroenterologist.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Ulcerative Colitis Market Characteristics
3. Ulcerative Colitis Market Trends And Strategies
4. Ulcerative Colitis Market - Macro Economic Scenario
5. Ulcerative Colitis Market Size And Growth
…..
27. Ulcerative Colitis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.